Pulmonary Vascular Permeability in Interstitial Lung Disease: A Positron Emission Tomographic Study

Kaplan, James D.; Trulock, Elbert P.; Anderson, D J; Schuster, Daniel P.

doi:10.1164/ajrccm/145.6.1495

Cited by 26 publications

(35 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glucose metabolism was also increased. Increased vascular permeability was noted by measuring the pulmonary transcapillary escape rate for gallium-labeled transferrin in pulmonary fibrosis [20]. However, these studies never progressed beyond the investigational phase.…”

Section: Discussionmentioning

confidence: 99%

Idiopathic Pulmonary Fibrosis: Evaluation with Positron Emission Tomography

Meißner

Hoo²,

Khonsary³

et al. 2006

Respiration

View full text Add to dashboard Cite

Background: The pathogenesis of interstitial lung disease remains under investigation, but may be related to increased inflammatory or cellular activity. This activity may be detectable with physiologic imaging. Objectives: We investigated the role of physiologic imaging using ¹⁸F-2-fluoro-2-deoxy-D-glucose (¹⁸FDG)-positron emission tomography (PET) scans in idiopathic pulmonary fibrosis (IPF). Methods: Seven male patients with histologically confirmed IPF underwent ¹⁸FDG-PET scans. Scans were analyzed qualitatively and interpreted as positive or negative. Patients also underwent pulmonary function tests and computed tomography (CT) scans. Results: The average total lung capacity was 71 ± 22% predicted (mean ± SD) and diffusing capacity for carbon monoxide was 44 ± 14% predicted. All had changes consistent with IPF on chest CT and 2 patients had ground glass attenuation. Six of seven patients (86%) had a positive ¹⁸FDG-PET scan. Changes in the ¹⁸FDG-PET scan were seen in 1 patient corresponding to changes in clinical status. Conclusions: Our findings suggest that ¹⁸FDG-PET scans may be helpful in the evaluation of IPF. Increased activity suggests active disease and changes in response to therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Idiopathic Pulmonary Fibrosis: Evaluation with Positron Emission Tomography

Meißner

Hoo²,

Khonsary³

et al. 2006

Respiration

View full text Add to dashboard Cite

show abstract

“…7 14 In preterm infants with RDS, a quantitative deficiency of surfactant may lead to secondary disruption of the endothelial–epithelial barrier. The studies of Jefferies et al , mentioned previously, as well as the identification of surfactant protein-A (molecular weight 35 000 Daltons) in the blood of premature infants with RDS provide evidence for loss of integrity of the alveolar epithelial–endothelial barrier and net flux from alveolus to vascular space 4…”

Section: Discussionmentioning

confidence: 99%

Measurement of protein flux with positron emission tomography in neonates

Nama

Kozlowski

Hamvas

1999

Archives of Disease in Childhood - Fetal and Neonatal Edition

View full text Add to dashboard Cite

/min). PTCER did not change between measurements in the infants with RDS, including five who received and responded to surfactant replacement between the two scans. Conclusions-Increased transvascular flux of large molecular weight proteins complicates RDS in preterm infants. PET provides a tool with which to evaluate the processes that contribute to pulmonary dysfunction in neonates. (Arch Dis Child Fetal Neonatal Ed 1999;80:F26-F29)

show abstract

“…This agent becomes localized to the lungs immediately after intravenous injection. Other applications of 68 Ga include evaluating vascular permeability in lung disease and in lung transplants (Kaplan et al, 1992a; Kaplan et al, 1992b). …”

Section: 68ga-labeled Pet Radiopharmaceuticalsmentioning

confidence: 99%

Clinical applications of Gallium-68

Banerjee

Pomper

2013

Applied Radiation and Isotopes

202

158

View full text Add to dashboard Cite

Gallium-68 is a positron-emitting radioisotope that is produced from a 68Ge/68Ga generator. As such it is conveniently used, decoupling radiopharmacies from the need for a cyclotron on site. Gallium-68-labeled peptides have been recognized as a new class of radiopharmaceuticals showing fast target localization and blood clearance. 68Ga-DOTATOC, 8Ga-DOTATATE, 68Ga-DOTANOC, are the most prominent radiopharmaceuticals currently in use for imaging and differentiating lesions of various somatostatin receptor subtypes, overexpressed in many neuroendocrine tumors. There has been a tremendous increase in the number of clinical studies with 68Ga over the past few years around the world, including within the United States. An estimated ~10,000 scans are being performed yearly in Europe at about 100 centers utilizing 68Ga-labeled somatostatin analogs within clinical trials. Two academic sites within the US have also begun to undertake human studies. This review will focus on the clinical experience of selected, well-established and recently applied 68Ga-labeled imaging agents used in nuclear medicine.

show abstract

Pulmonary Vascular Permeability in Interstitial Lung Disease: A Positron Emission Tomographic Study

Cited by 26 publications

References 4 publications

Idiopathic Pulmonary Fibrosis: Evaluation with Positron Emission Tomography

Idiopathic Pulmonary Fibrosis: Evaluation with Positron Emission Tomography

Measurement of protein flux with positron emission tomography in neonates

Clinical applications of Gallium-68

Contact Info

Product

Resources

About